High incidence of independent second XXXX after non-muscle-invasive @entity150 .

@entity1 @entity2558 @entity263 @entity5 @entity2 @entity150
OBJECTIVE: The incidence of @entity5 is constantly increasing as a result of over-proportional ageing of the population in industrialized nations. Follow-up of non-muscle-invasive @entity150 (NMIBC) primarily relies on the detection of either relapse or progression and does not include screening for second @entity5 . This study investigated the incidence of independent non-urothelial second @entity5 and associated risk factors in @entity1 with NMIBC. MATERIAL AND METHODS: The charts of 380 consecutive @entity1 (297 @entity1 and 83 @entity1 ) with newly diagnosed NMIBC over a 16-year period at a Swiss hospital were analysed retrospectively. Age, stage of @entity150 , smoking status, and occurrence of second and third @entity5 were registered. Observed incidences of independent non-urothelial @entity5 were compared with age- and gender-specific rates based on data from the National Institute for @entity5 Epidemiology and Registration by calculating standardized incidence ratios (SIRs). RESULTS: Mean age at first NMIBC diagnosis was 69.9 years. Histological stage of the NMIBC was pTa in 241 @entity1 (63.4%), @entity2558 in 102 (26.8%)and pTis in 37 (9.7%). During follow-up, 62 independent non-urothelial second or third @entity5 were observed in 48 @entity1 (16.2%) and 10 @entity1 (12.0%). In male @entity1 , @entity263 (SIR 4.3 and 5.7, respectively) were more frequent than expected in the general population, as were lung and uterine @entity5 in @entity1 . CONCLUSIONS: Follow-up in @entity1 with NMIBC should pay special attention to independent non-urothelial @entity5 . Investigations for non-urological @entity5 , especially for @entity2 , should form part of the standard follow-up in NMIBC @entity1 .
